Our Approach
Tackling the roots of cardiac diseases
The heart is the central engine of the human body and cardiac dysfunction remains the leading cause of death world-wide. Heart diseases represent an increasing burden for families and the healthcare system globally with prevalence, hospitalization and mortality rates far exceeding those of other diseases. Current treatment options primarily alleviate the symptoms and do not address the underlying root causes, despite decades of research and development in all areas related to cardiac diseases and heart failure.
Non-coding RNAs: A new frontier in addressing cardiac diseases
Our goal at Cardior is to identify and counteract the molecular mechanisms of the broad area of ischemic-induced heart failure as well as specific cardiac diseases such as hypertrophic and dilated cardiomyopathies. Our innovation is based on a novel class of RNA therapeutics targeting so called non-coding RNAs that are able to act on several key disease pathways simultaneously, triggering a concerted therapeutic effect against key hallmarks of heart disease including:
- Cardiac hypertrophy
- Fibrosis
- Impaired contractility
- Reduced vascularization
Although non-coding RNAs (ncRNAs) are not translated into proteins, they are critical for the regulation of important cellular processes and their dysregulation is a hallmark of many diseases. With its deep knowledge in RNA biology, Cardior has developed a therapeutic approach to restore normal levels and functions of these critical players in the pathological processes of cardiac diseases.
Our lead candidate
CDR132L is an oligonucleotide-based inhibitor directed against miRNA132 (miR-132), designed to halt and reverse the development of detrimental cardiac remodeling.
CDR132L selectively blocks aberrant miR-132 levels leading to the reversal of cellular pathology and restoration of normal function in cardiomyocytes contributing to improved cardiac systolic and diastolic function in patients with heart failure.
CDR132L is a highly stable water-soluble oligonucleotide formulated for parenteral or subcutaneous application.
CDR132L is currently being evaluated in HF-REVERT Phase 2 Clinical Study and has the potential to prolong patients’ life and improve their quality of life.
Mode of action
Our pipeline
We are advancing a novel class of cardiac therapeutics with a unique and revolutionary mode of action. By modulating disease pathways at the cellular level, we are pioneering a restorative approach for a class of diseases which affect large portions of the population. Due to the lack of therapies that address the underlying causalities, the high level of medical need is yet unmet. Therefore, we will continue to develop and expand our therapeutic pipeline independently and together with partners.
- Program
- CDR132L
- Indication
- Post-Myocardial Infarction (MI) Heart Failure
- MoA
- Interaction with miR - 132
- Development Stage
-
- Program
- CDR132L
- Indication
- Heart Failure with Preserved Ejection Fraction
- MoA
- Interaction with miR - 132
- Development Stage
- Program
- CDR132L
- Indication
- Dilated Cardiomyopathy
- MoA
- Interaction with miR - 132
- Development Stage
- Program
- CDR348T
- Indication
- Hypertrophic Cardiomyopathy
- MoA
- Modulation of ncRNAs
- Development Stage
- Program
- CDR641L
- Indication
- Hypertrophic Cardiomyopathy
- MoA
- Interaction with ncRNA
- Development Stage
- Program
- Undisclosed
- Indication
- Diverse Indications
- MoA
- Interaction with ncRNAs
- Development Stage
